
FDTX aims for long-term capital growth by utilizing Fidelitys disruptive strategies which identify global technology companies perceived to disrupt market conditions or displace incumbents over time. These companies are those that, in the adviser's opinion, are engaged in big data, machine learning, AI, cloud computing, cybersecurity, e-commerce and consumer technologies, rideshare, battery technology, and next-generation hardware. The portfolio is constructed using a fundamental analysis of factors like financial, market, and economic conditions, and industry positions. FDXT converted from a…
Is FDTX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

While large-cap technology companies, including the Magnificent Seven, often account for a substantial share of market-cap weighted index allocations, investors may consider a range of opportunities across the broader market to align with their investment objectives.

Fidelity Disruptive Technology ETF earns a Buy rating for its concentrated, actively managed portfolio targeting top AI infrastructure and compute names. FDTX differentiates itself by focusing on market leaders like NVDA, TSM, MSFT, AMZN, GOOG, and META, avoiding diluted exposure found in equal-weight peers. The fund's 0.50% expense ratio is competitive for active management, with disciplined portfolio turnover and a clear thesis aligned with AI capital expenditure trends.

As the market faces more and more concentration risk from the dominance of just a few AI hyperscalers, investors are on the lookout for ETF tools to diversify their portfolios while still chasing upside.

Fidelity Disruptive Technology ETF (FDTX) earns a Buy for its concentrated, actively managed exposure to leading AI infrastructure and compute names. FDTX's top holdings—TSM, NVDA, MSFT, AMZN, GOOG, META—anchor it at the upper end of the AI value chain, driving recent outperformance. The fund's 0.50% expense ratio is competitive for active management, and its 42% turnover signals disciplined, thesis-driven portfolio construction.

If you searched for a biotech or health sciences ETF and landed on Fidelity Disruptive Technology ETF (NYSEARCA:FDTX), there is something important to clarify upfront: this fund carries zero healthcare sector exposure.